119. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Well Tolerated

BACKGROUND: RSV is a common cause of respiratory acute illness in older adults (OA). We evaluated safety and reactogenicity of RSVPreF3 candidate vaccine in young adults (YA) and OA. METHODS: In this phase I/II, placebo-controlled, multi-country trial (NCT03814590), YA aged 18–40 years were randomiz...

Descripción completa

Detalles Bibliográficos
Autores principales: Tica, Jelena, Guiñazú, Javier Ruiz, Andrews, Charles P, Davis, Matthew G, Essink, Brandon, Fogarty, Charles, Kerwin, Edward, Leroux-Roels, Isabel, Steenackers, Katie, Vandermeulen, Corinne, David, Marie-Pierre, Dezutter, Nancy, Fissette, Laurence, Koch, Juliane, Mesaros, Narcisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778015/
http://dx.doi.org/10.1093/ofid/ofaa439.429

Ejemplares similares

Ejemplares similares